Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Bruton tyrosine kinase inhibitors (BTKi) and venetoclax are currently used to treat newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). However, most patients eventually develop resistance to these therapies, underscoring the need for effectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Siddiqi, Tanya, Soumerai, Jacob D., Dorritie, Kathleen A., Stephens, Deborah M., Riedell, Peter A., Arnason, Jon, Kipps, Thomas J., Gillenwater, Heidi H., Gong, Lucy, Yang, Lin, Ogasawara, Ken, Thorpe, Jerill, Wierda, William G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652916/
https://www.ncbi.nlm.nih.gov/pubmed/34699592
http://dx.doi.org/10.1182/blood.2021011895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652916/
https://www.ncbi.nlm.nih.gov/pubmed/34699592
http://dx.doi.org/10.1182/blood.2021011895

Ejemplares similares